|
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy. |
|
|
Honoraria - Amgen; Astellas Pharma; Janssen-Ortho; Sanofi |
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Ipsen; Janssen; Orion; Sanofi |
|
|
No Relationships to Disclose |
|
|
Research Funding - Celgene; Ipsen; Lilly; Merck; Roche; Sanofi |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Ipsen; Janssen; Sanofi |
Research Funding - Bayer (Inst); Ipsen (Inst); Merck (Inst); Pierre Fabre (Inst); Sanofi (Inst) |
|
|
No Relationships to Disclose |
|
Antoine Thiery- Vuillemin |
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Ferring; Ipsen; Janssen; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Janssen; Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Genentech; Merck; Pfizer; Pierre Fabre |
Research Funding - Millennium (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - MSD Oncology; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Pfizer; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Argos Therapeutics; Astellas Pharma; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Ipsen; Janssen; Lilly/ImClone; Merck; Millennium; Novartis; Oncogenex; Pfizer; Roche; Sanofi; Takeda |
Travel, Accommodations, Expenses - Bayer; Novartis |
|
|
|
|
|
|
|
|
No Relationships to Disclose |